This biotech company develops mechanism-based therapies for blood, immune, and metabolic diseases by cloning and analyzing genes important for blood formation. They utilize zebrafish, mice, and human-induced pluripotent stem cells to identify novel therapeutic targets.
Funding
Funding not disclosed
Founders
Product
Problem
Patients requiring hematopoietic stem cell transplants (HSCT) often face significant challenges in finding fully matched donors, leading to delays and increased risk of graft-versus-host disease (GvHD). The current reliance on donor availability limits access to potentially curative treatments for severe blood and immune disorders.
Solution
Stratus Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies designed to eliminate the need for matched donors and provide immediate access to potentially life-saving treatments. The company's Stratus Prime™ platform generates Prime HSCs™ and Prime HPCs™ that drive durable, long-term engraftment and full hematopoietic system restoration. Stratus' lead product, ST-101, is engineered to deliver a high proportion of Prime HSCs™ without T-cells, reducing the risk of GvHD and enabling rapid immune reconstitution. By offering HLA-compatible, transgene-free HSCs, Stratus aims to overcome the limitations of traditional transplant approaches and expand access to curative therapies for a range of malignant and non-malignant blood and immune disorders.
Target Audience
The primary target audience includes patients with acquired or inherited bone marrow failure syndromes (BMFS) and transfusion-dependent beta thalassemia (TDT), as well as physicians seeking to expand access to effective and safe stem cell transplantation options.
Features
- Stratus Prime™ platform for generating off-the-shelf, durable hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs)
- ST-101, a lead product containing both Prime HSCs™ and Prime HPCs™ for near-term immune recovery and durable, long-term engraftment
- HSCs generated via PIEZO1 activation, a novel method for producing long-term reconstituting, transgene-free HSCs from embryonic hemogenic endothelial cells and human pluripotent stem cells (hPSCs)
- Engineered to deliver a high proportion of Prime HSCs™ in the absence of T-cells to reduce or eliminate the risk of graft-versus-host disease
- HLA-compatible to eliminate the search associated with finding donors
- Designed to mitigate the challenges of conventional conditioning regimens